03May 2021
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer approval of ICB treatment for any TMB-H tumor, as assessed by the targeted FoundationOne CDx assay in nine tumor types, the utility of this biomarker has not been fully demonstrated across all cancers.

  • #oncology

Like

Save

Share